Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TANZEUM is a fusion protein injectable approved by GSK in 2014 for diabetes management. The specific mechanism of action and indications are not fully detailed in available data, but as a fusion modality it represents an innovative approach to metabolic disease treatment. This product operates in a competitive therapeutic landscape with established diabetes care standards.
Peak
Product is in peak commercial stage; commercial teams maintain established market presence with moderate competitive pressure at 30%.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TANZEUM careers center on sustaining market position and defending against 30% competitive pressure in the diabetes space. Roles emphasize brand management, MSL engagement, and reimbursement strategy rather than pipeline development.
Brand ManagerMedical Science Liaison
Worked on TANZEUM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.